Skip to main content
Heritage Bio Labs · Research use only
Heritage Bio Labs

ACE-083Interpret the evidence

Why bigger muscles did not settle the FSHD trial

1 numbered sourceSource years 2022

A peptide is a short chain of amino acids connected by peptide bonds. Peptides can help carry signals between cells or interfere with signals that are already present. ACE-083 is an investigational fusion protein based on follistatin. It was engineered to sequester myostatin, activins and other signals around a targeted muscle. The older 2022 trial in adults with facioscapulohumeral muscular dystrophy, known as FSHD, asked whether an increase in local muscle volume would translate into a change people could use in daily life. [1]

FSHD can affect some muscles much more than others. That pattern provided the rationale for studying a locally acting protein. The trial investigated the biceps of the upper arm and the tibialis anterior on the front of the lower leg. In the randomized, blinded phase, participants received ACE-083 or a placebo in the targeted muscle group. The MRI outcome was chosen to test whether the experimental protein changed those muscles at the tissue level. The investigators also looked at strength, movement and how participants described their own function. [1]

Of 58 people enrolled in the randomized phase, 55 were evaluable. The estimated difference in total muscle volume between ACE-083 and placebo favored ACE-083 by 16.4% in the biceps group and 9.5% in the tibialis anterior group. The estimated volume of tissue capable of contraction also increased in both groups. Fat fraction decreased in the lower-leg group. These measurements provide evidence that the local intervention changed the composition and dimensions of the muscles studied. [1]

A walk, stair climb or reaching task depends on multiple muscle groups, coordination and the severity of disease outside the target muscle. The researchers tailored their functional tests to the treated region. They used lower-limb tasks such as walking and climbing for the leg group and an upper-limb performance measure for the arm group. They found no consistent improvements in function or in outcomes reported by participants. The most frequent adverse events were mild or moderate reactions at the injection site. [1]

The distinction matters when choosing an endpoint. A scan can reveal an effect close to the site and mechanism of a drug. A movement test asks whether that effect is large enough and integrated enough to change performance. A report from a participant captures a further dimension, whether the experience of living with the disease changed. The trial documented the first type of effect under its study conditions. It left the clinical value of the volume change unresolved. [1]

Sources

Original works cited in this article. Links open the external record in a new tab.

Shop ACE-083

Articles from the Heritage Bio Labs research series, with links to the original sources. For research use only; not medical advice. Also available as Markdown or JSON.